Hikma Pharmaceuticals PLC (OTCMKTS:HKMPF) Given Average Rating of “Buy” by Analysts

Hikma Pharmaceuticals PLC (OTCMKTS:HKMPFGet Rating) has earned a consensus recommendation of “Buy” from the seven analysts that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $2,500.00.

Several equities analysts have issued reports on the stock. Zacks Investment Research cut shares of Hikma Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, May 4th. Morgan Stanley reduced their price target on shares of Hikma Pharmaceuticals from GBX 2,300 ($28.94) to GBX 2,100 ($26.43) in a research report on Friday, May 6th. Finally, JPMorgan Chase & Co. reduced their price target on shares of Hikma Pharmaceuticals from GBX 3,000 ($37.75) to GBX 2,900 ($36.49) in a research report on Wednesday, March 2nd.

HKMPF opened at $20.82 on Wednesday. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.38 and a current ratio of 2.06. The company’s 50-day simple moving average is $25.55 and its two-hundred day simple moving average is $27.39. Hikma Pharmaceuticals has a 52-week low of $20.82 and a 52-week high of $37.70.

Hikma Pharmaceuticals Company Profile (Get Rating)

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded.

Read More

Analyst Recommendations for Hikma Pharmaceuticals (OTCMKTS:HKMPF)

Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.